Suppression mechanisms of COX assembly defects in yeast and human: Insights into the COX assembly process  by Barrientos, Antoni et al.
Biochimica et Biophysica Acta 1793 (2009) 97–107
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrReview
Suppression mechanisms of COX assembly defects in yeast and human:
Insights into the COX assembly process
Antoni Barrientos a,b,⁎, Karine Gouget a, Darryl Horn b, Ileana C. Soto b, Flavia Fontanesi a
a Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA
b Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA⁎ Corresponding author. Departments of Neurology an
Biology, The John T. Macdonald Center for Medical Genet
School of Medicine, 1600 NW 10th Avenue, RMSB # 2067
305 243 86 83; fax: +1 305 243 39 14.
E-mail address: abarrientos@med.miami.edu (A. Bar
0167-4889/$ – see front matter © 2008 Elsevier B.V. Al
doi:10.1016/j.bbamcr.2008.05.003a b s t r a c ta r t i c l e i n f oArticle history: Eukaryotic cytochrome c ox
Received 11 March 2008
Received in revised form 29 April 2008
Accepted 5 May 2008
Available online 15 May 2008
Keywords:
Mitochondria
Cytochrome c oxidase
Suppression
Mitochondrial disorder
COX assemblyidase (COX) is the terminal enzyme of the mitochondrial respiratory chain. COX is
a multimeric enzyme formed by subunits of dual genetic origin whose assembly is intricate and highly
regulated. In addition to the structural subunits, a large number of accessory factors are required to build the
holoenzyme. The function of these factors is required in all stages of the assembly process. They are relevant
to human health because devastating human disorders have been associated with mutations in nuclear genes
encoding conserved COX assembly factors. The study of yeast strains and human cell lines from patients
carrying mutations in structural subunits and COX assembly factors has been invaluable to attain the current
state of knowledge, even if still fragmentary, of the COX assembly process. After the identiﬁcation of the
genes involved, the isolation and characterization of genetic and metabolic suppressors of COX assembly
defects, reviewed here, have become a proﬁtable strategy to gain insight into their functions and the
pathways in which they operate. Additionally, they have the potential to provide useful information for
devising therapeutic approaches to combat human disorders associated with COX deﬁciency.
© 2008 Elsevier B.V. All rights reserved.1. Eukaryotic cytochrome c oxidase assembly in health and diseaseThe fundamental mechanism by which respiratory energy trans-
duction occurs in mitochondria and aerobic bacteria is the coupling of
electron transfer reactions to the formation of transmembrane electro-
chemical gradients [1]. In eukaryotes, cytochrome c oxidase (COX) or
complex IV, the terminal enzyme of the mitochondrial respiratory
chain, is one of the primary coupling sites. COX is amultimeric copper-
heme A metalloenzyme that functions as an electron-driven proton
pump. It catalyzes the transfer of electrons from ferrocytochrome c to
molecular oxygen via its four redox active metal co-factors. Fig. 1
summarizes the catalytic metal centers and the electron transfer
pathway in COX. Electrons enter COX through a mixed valence
dinuclear copper center, the CuA site, located in subunit 2. Electrons
are transferred from CuA to a low-spin heme a located in subunit 1 and
are subsequently transferred intra-molecularly to the active sitewhere
a high-spin heme a3 and CuB form a binuclear center for oxygen
binding. The mechanism of electron transfer through COX has been
extensively studied (reviewed in [2–4]). From an evolutionary point of
view, the presence of the CuA center deﬁnes COX and distinguishes thisd Biochemistry and Molecular
ics, Universtiy of Miami, Miller
, Miami, FL 33136, USA. Tel.: +1
rientos).
l rights reserved.enzyme from other terminal oxidases that use quinol rather than
cytochrome c as the electron donor [2,5,6]. The electron transfer
reaction is coupled to the vectorial transfer of protons from the matrix
to the intermembrane space thus contributing to the generation of the
proton gradient which is subsequently used by the F1F0 mitochondrial
ATPase to drive the synthesis of ATP. The mechanism of proton
pumping has been the focus of intense study and has been recently
reviewed elsewhere ([7] and [8]).
Eukaryotic COX is formed by 11–13 subunits (11 in the yeast Sac-
charomyces cerevisiae and 13 in mammals) of dual genetic origin.
Subunits 1, 2 and 3 form the catalytic core of the enzyme and in the
majority of eukaryotes are encoded in the mitochondrial DNA. The
core is surrounded by a set of nuclear-encoded small subunits that are
important for both the assembly and function of the enzyme as well as
its dimerization (reviewed in [9,10]). These subunits are also involved
in the modulation of the catalytic activity and in the protection of the
core from reactive oxygen species. A list of COX homologue subunits in
yeast and mammals is shown in Table 1.
As a consequence of its central role in oxidative metabolism, COX
has been intensively studied by biochemical, genetic, spectroscopic,
and crystallographic means [11–13]. From these studies it is known
that other metals such as zinc and magnesium are also bound to the
enzyme, although the basis for their speciﬁc requirements are largely
unknown. The zinc atom could play a role in structural stability of the
complex [14]. The magnesium/manganese site is in close proximity to
the H2O exit channel and is thought to aid in the stability and release
of H2O produced during the reduction of O2 [15].
Fig. 1. Cytochrome c oxidase. Representation of the complex, showing the two catalytic
subunits (subunits 1 and 2) involved in electron transfer from cytochrome c to
molecular oxygen. The mechanism of electron transport, coupled to proton pumping, is
depicted. Subunit 2 contains the binuclear CuA center that receives electrons from
cytochrome c. In subunit I, a low-spin heme (heme a) accepts electrons from CuA and
transfers them to a binuclear center consisting of a high-spin heme (heme a3) and a
copper atom (CuB). Within the binuclear center, molecular oxygen is bound to heme a3
and sequentially reduced to water. IMS, intermembrane space; MIM, mitochondrial
inner membrane.
Table 1
Homologue COX subunits and COX assembly factors in yeast and mammals
Yeast Mammals Function
Gene Protein Gene Protein
Catalytic core (mtDNA-encoded structural subunits)
COX1 Cox1p MTCOXI COX1 Catalytic subunits
COX2 Cox2p MTCOXII COX2
COX3 Cox3p MTCOXIII COX3 Catalytic core stability?
Core protective shield (nDNA encoded structural subunits)
COX4 Cox4p COXVb COX5b Subunits required for COX assembly
and functionCOX5a Cox5ap COXIV-1 COX4-1
COX5b Cox5bp COXIV-2 COX4-2
COX6 Cox6p COXVa COX5a
COX7 Cox7p COXVIIa COX7a
COX9 Cox7ap COXVIc COX6c
– – COXVIIb COX7b
– – COXVIII COX8
COX8 Cox8p COXVIIc COX7c
COX12 Cox9p COXVIb COX6b Non-essential subunits
COX13 Cox10p COXVIa COX6a
Membrane insertion and processing of catalytic core subunits
OXA1 Oxa1p OXA1 OXA1 Membrane insertion of COX subunits,
cytochrome b and ATPase proteolipid
COX20 Cox20p COX20 COX20 Cox2p chaperone. Presentation of
Cox2p-precursor to the IMP complex
COX18 Cox18p COX18 COX18 Export of the Cox2p C-terminus tail
MSS2 Mss2p – – Export of the Cox2p C-terminus tail
PNT1 Pnt1p – – Export of the Cox2p C-terminus tail
IMP1 Imp1p – – Responsible for the maturation of Cox2p
IMP2 Imp2p IMMP2L IMMP2L Necessary for the stability and activity of Imp1
SOM1 Som1p – – Third component of the yeast IMP complex.
It could play a role in substrate recognition
Copper metabolism and insertion
COX17 Cox17p COX17 COX17 Delivery of copper to Sco1p and Cox11p
SCO1 Sco1p SCO1 SCO1 Transfer of copper to COX and/or reduction
of cysteine residues in subunit 2SCO2 SCO2
COX11 Cox11p COX11 COX11 Stable formation of the Cu(B) and
magnesium centers
COX19 Cox19p COX19 COX19 CX9C proteins. They could play roles in
redox control and copper trafﬁcking in
the intermembrane space
COX23 Cox23p COX23 COX23
PET191 Pet191p PET191 PET191
CMC1 Cmc1p CMC1 CMC1
Heme A biosynthesis
COX10 Cox10p COX10 COX10 Farnesylation of protoheme
COX15 Cox15p COX15 COX15 Hydroxylation of heme O
Assembly/unknown
COX16 Cox16p COX16 COX16 Unknown function
PET117 Pet117p – – Unknown function
PET100 Pet100p – – Formation of assembly intermediates
containing Cox7p, Cox8p, and Cox9p
SHY1 Surf1p SURF1 SURF1 Catalyzes an assembly step in which
Cox1p is one of the partners
MSS51 Mss51p – – Required for translation of COX1 mRNA.
Additionally, binds Cox1p and is required
for its stability/ maturation/assembly
COX14 Cox14p – – Binds Cox1p and is required for its stability/
maturation/assembly
COA1 Coa1p – – Binds Cox1p and is required for its stability/
maturation/assembly
Genes involved in expression of the mitochondrial DNA-encoded subunits and in
mitochondrial import of nuclear-encoded subunits are not included.
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factors being added in an ordered manner. Data obtained from
analyses of the human enzyme performed by Blue-Native electro-
phoresis suggests an assembly pathway characterized by the
sequential incorporation of COX subunits. Assembly is initiated
around a seed formed by subunit 1 and proceeds with the formation
of several discrete assembly intermediates probably representing
rate-limiting steps in the process [16].
Analysis of assembly intermediates has given insights into the
overview of the assembly process, but it has provided very limited
information about additional players involved and their speciﬁc roles.
To disclose the non-structural ancillary factors involved in COX
assembly, a proﬁtable strategy has been to systematically analyze
yeast mutants defective in COX assembly. This approach was followed
with the goal of identifying the functions of the gene products
responsible for the COX defective phenotype to subsequently recon-
struct the different steps of the assembly pathway. Screens of nuclear
respiratory deﬁcient mutants have revealed the existence of a large
number of nuclear genes coding for accessory factors that selectively
affect expression of this respiratory complex in yeast [17,18]. Their
functions, required for all steps of the process and signiﬁcantly con-
served fromyeast to humans, are summarized inTable 1 and have been
previously reviewed [9,19,20].
Over the last 15 years, COX biogenesis has received signiﬁcant
attention because of its medical relevance. Defective COX biogenesis
results in mitochondrial diseases frequently involving brain, skeletal
muscle and heart tissues (reviewed in [21–23]). To date, all Mendelian
disorders presenting COX deﬁciency have been assigned to mutations
in ancillary factors. Speciﬁcally, mutations have been found in SURF1,
required for the formation of early assembly intermediates [24,25],
SCO1 and SCO2, required for COX copper metallation [26–30], COX10
and COX15, essential for heme A biosynthesis [31–33], and LRPPRC,
required for the expression of COX subunits [34].
Mutant ﬁbroblast cell lines from patients suffering from some
of these disorders have been used to reﬁne the proposed sequentialmodel for COX assembly by studying the accumulation of subassembly
intermediates in the absence of speciﬁc COX assembly factors [35–37].
These studies, described below, have provided information concern-
ing the assembly step either catalyzed or affected by the mutated
factor. In contrast, the study of assembly intermediates in yeast has
been restricted since they do not seem to accumulate in detectable
amounts [37]. The accumulation of assembly intermediates in most
yeast COX mutants is probably limited by the small amount of Cox1p
99A. Barrientos et al. / Biochimica et Biophysica Acta 1793 (2009) 97–107that is newly synthesized in the absence of fully assembled COX [38].
However, subassemblies have been recently detected in yeast cox2
[39] and pet100mutants [40] and seem to be similar to those observed
in mammalian cells.
After the identiﬁcation of the genes involved, the further
exploitation of the yeast paradigm by isolating and characterizing
genetic and metabolic suppressors of COX assembly defects, reviewed
here, has become a rewarding effort to gain insight into the functions
of these genes and the pathways in which they operate. The genetic
suppressors can be classiﬁed in two general groups, extragenic and
intragenic. Intragenic suppressors restore function to a protein at a site
different from the primary mutation. They are very useful for example
to understand the roles of several domains in a protein or the role of a
particular residue and their tertiary structure neighbors within a
protein. Extragenic suppressors, instead, reconstitute function in a
system either by mutating a protein to work with another mutated
protein or by bypassing the requirement of the ﬁrst protein. Here, we
will review exclusively some cases of extragenic suppression of COX
assembly defects. Extragenic suppressors of strains carrying a null
allele of a particular gene can arise naturally by a spontaneous
mutation in a gene that compensates for the absence of the ﬁrst gene.
These natural suppressors are rare. In the cases of the respiratory
deﬁcient COX assembly mutants, only a few yeast strains sponta-
neously revert to a respiratory-competent phenotype (Table 2). The
hunt for genetic suppressors is designed to identify additional
mutations that restore a particular aspect of COX assembly and/or
its respiratory capacity to the initial mutant. The characterization of
these suppressor mutations has lead to the identiﬁcation of new genes
with functions related to the initial mutated gene. These studies have
also suggested interactions between proteins that participate in a
common pathway. Another often-used means for uncovering inter-
acting proteins in a common pathway is suppression by overexpres-
sion of wild-type alleles. Suppression caused by overexpression can
occur by many different mechanisms but in general the necessity of
the mutated protein is bypassed. Additionally, the characterization of
these genetic suppressors in combination with the identiﬁcation ofTable 2
Genetic and metabolic suppressors of COX deﬁciencies in cellular and animal models as
well as in human patients
Mutated
gene
Genetic suppressors Metabolic/
pharmacologic
suppressors
Spontaneous extragenic
suppressors
High copy suppressors
Yeast cultures
COX5a ROX1 [51] ORD1 [52]
OXA1 CYT1 [144] HAP4 [132]
OMS1 [145]
RMD9 [146]
IMP1 SOM1 [147]
COX17 SCO1 [71] SCO2 +
Copper [71]
Copper [61]
SCO1 SCO2 [71]
COX23 COX17+Copper [68]
SHY1 MSS51 [112] MSS51 [112] HAP4 [128]
COX5a + COX6 [128]
Copper [128]
COA1 MSS51 [123] COX10 [123]
MDJ1 [123]
Human cell cultures
SURF1 NF-YA [128]
SCO2 Copper [91,148]
COX10 PPAR agonists
[104]
COX1 PGC1-α [143] PGC1-α [143]
Human patients
SCO2 Copper [93]
Intragenic suppressors are not listed.pharmacological suppressors have the potential to provide useful
information for devising therapeutic approaches to combat human
disorders associated with COX deﬁciency.
The aim of this review is to summarize some of the understanding
concerning COX assembly that has been obtained by studying dif-
ferent classes of suppressors. The information obtained by the study of
suppressors of mitochondrial gene expression [41] and of defects in
the membrane insertion and processing of mtDNA-encoded COX
subunits ([42] and listed on Table 2) has been reviewed elsewhere. We
have focused on describing some of the knowledge obtained by
studying suppressors of structural, heme A biosynthesis, copper
metabolism and insertion defects and alterations in the formation of
assembly intermediates.
2. Suppression of cytochrome c oxidase biogenesis defects in yeast
and human
2.1. Suppressors of structural defects
Some nuclear-encoded subunits have evolved isoforms that allow
the enzyme to regulate its activity depending on environmental
factors. For example, subunit Cox5p in the yeast S. cerevisiae exists in
two isoforms, Cox5ap and Cox5bp, which are expressed according to
oxygen availability. In humans, tissue speciﬁc isoforms have been
reported for four nuclear-encoded subunits, including COX4, the
homologue of yeast Cox5p [43,44]. Studies on suppressors of yeast
cox5a mutants have given insight into oxygen regulation of COX
subunits and their switch to modulate COX enzymatic activity.
Yeast Cox5ap and Cox5bp share 66% sequence homology [45]. The
presence of either one or the other isoform confers different kinetic
properties to the holoenzyme. Moreover, the transmembrane α-helix
of Cox5p interacts with Cox1p and it is able to alter, depending on the
isoform, the protein environment around the binuclear center. The
Cox5bp-containing enzyme has a higher maximal turnover, since
electron transfer from heme a to heme a3 occurs three to four times
faster than in the Cox5ap-containing isoenzyme [46]. The expression of
COX5a and COX5b genes is regulated by oxygen availability [47]. In
normoxia, the expression of COX5a is induced by the heme-dependent
transcriptional activatorHap2p/3p/4p/5p complex,whileCOX5b expres-
sion is repressed, also in a heme-dependent fashion [48]. When the
environmental oxygen concentration decreases below 0.5 μM, a switch
in Cox5p isoform expression takes place [49]. The change results from
the consequence of low heme biosynthesis, a process that requires
oxygen [50]. Due to the lack of induction of COX5a and the lack of
repression of COX5b, Cox5bp is expressed and used to assemble a more
efﬁcient COX holoenzyme. By this means, ATP production is maximized
under hypoxia while minimizing ROS generation. In this way, by
regulating COX isoforms composition, yeast cells can rapidly respond to
changes in environmental oxygen concentration.
The oxygen regulation of these genes has been exhaustively studied
in the yeast S. cerevisiae taking advantage of the ability of a respiratory
deﬁcient Δcox5a strain to spontaneously revert to a respiratory-
competent phenotype. Two different revertant complementation
groups were isolated and analyzed [51,52]. In both cases, the reversion
was accounted for by recessivemutations in a single nuclear gene. These
mutations do not bypass the subunit 5 requirement. The mechanism of
reversion rather consists of an increase in COX5b expression in
normoxia. The cloning of the suppressor genes allowed the identiﬁca-
tion of twonewplayers in theoxygen regulatory pathway: Reo1p/Rox1p
and Ordlp/Ixr1p, two transcriptional repressors of COX5b gene [51,52].
Rox1p is a general hypoxic regulator that represses a large group of
hypoxic genes, including COX5b, during aerobic growth. In normoxia,
ROX1 is induced by the heme-binding transcriptional activator Hap1p
[53]. In the absence of oxygen, ROX1 expression is down-regulated and
the repression of COX5b is released [51]. Rox1p levels are tightly
regulated in the cell and additional regulatory factors of ROX1 have been
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Mot3p, another general repressor of hypoxic genes, has been recently
reported, enlarging our understanding of the complex pathway of
oxygen-dependent gene regulation [55]. In contrast to Rox1p, Ord1p is
an oxygen dependent but Hap1p independent speciﬁc COX5b repressor
[52]. Both Rox1p and Ord1p bind to the same 44 bp Upstream
Repression Sequence in the promoter of COX5b gene [52]. Currently, it
remains unknown how Ord1p expression or function is regulated
by oxygen and which kind of functional interactions (competition/
cooperation) exist between Rox1p and Ord1p. The physiological sig-
niﬁcance for the existence of multiple COX5b repressors probably lies in
the necessity to achieve a large range of gene expression variations in
response to oxygen availability.
Noteworthy, COX isoform oxygen-dependent expression is highly
conserved from lower to higher eukaryotes. Inmammals, COX subunit 4,
the homologue of yeast subunit 5, also exists in two isoforms, COX4-1
and COX4-2. As their yeast counterparts, they are regulated by oxygen
and confer different kinetic properties to the holoenzyme [56]. The
regulation of the mammalian isoform switch seems to be regulated
differently than in yeast. Homologues of the main yeast regulatory
elements have not been found in mammals. The regulation of COX4
isoformexpression in response to oxygen availability is insteadmediated
by the hypoxia-inducible factor 1α (HIF-1 α) (reviewed in [57]). In
aerobic conditions, HIF-1α is hydroxylated in an oxygen-dependent
reaction and degraded by the proteosome [58]. During hypoxia,
hydroxylation is inhibited; HIF-1α is not degraded and accumulates in
the cell. Consequently, HIF-1α induces transcription of both, theCOXIV-2
gene and the gene encoding for the mitochondrial protease LON,
responsible for the degradation of COX4-1 [59]. Like in yeast, the COX4
isoform switch in mammals is a fundamental cellular adaptive response
to maintain the efﬁciency of respiration under conditions of reduced
oxygen availability. Additionally,whileCOXIV-1 is ubiquitously expressed
in all tissues, COXIV-2 is expressed at particularly high levels in the lungs
and trachea [56]. Huttemann et al. have proposed that the expression of
COX4-2 isoform in these highly oxygenated tissues can have a
physiological protective function by increasing electron transfer efﬁ-
ciency and consequently decreasing ROS formation [60].
2.2. Suppressors of copper insertion defects
The analyses of suppressors of copper insertion defects have
allowed for the identiﬁcation of factors involved in mitochondrial
copper metabolism and the COX copper insertion pathway as well as
for the development of therapeutic approaches.
COX copper metallation involves the function of several conserved
proteins located in themitochondrial intermembrane space (IMS) that
were initially identiﬁed in yeast. The ﬁrst protein involved in this
function was the IMS chaperone Cox17p [61], a small soluble
hydrophilic protein which binds copper(I) ions [62] through a CCxC
metal binding motif. Cox17p also contains a twin Cx9C structural
motif. Mutational analyses in yeast have shown that while the ﬁrst
cysteine in the Cx9C motif is part of the copper-binding motif, the
remaining three conserved cysteines are not important for Cox17p
copper-binding function [63]. However, structural studies on human
COX17 have recently shown that the two adjacent cysteines in the
CCxC domain are actually the copper-binding cysteines [64]. Cox17p
has a dual location in the IMS and in the cytoplasm. The respiratory
deﬁcient phenotype of cox17 null mutant strains can be rescued by
supplementation of high copper concentrations to the media or by
signiﬁcantly lower concentrations in combination with overexpres-
sion of CTR1 (the structural gene for the plasma membrane copper
pump) [61]. This suppression was the basis to propose that Cox17p
could be shuttling copper from the cytoplasm into the mitochondrial
intermembrane space [61,62]. This hypothesis has been challenged by
the fact that the tethering of Cox17p to the inner mitochondrial
membrane does not affect COX assembly [65]. Nevertheless, the exog-enous copper suppression studies were very useful to place Cox17p
in the COX copper delivery pathway. The copper source for COX
metallation seems to be a matrix pool of copper bound by a low
molecular weight non-proteinaceous ligand [65,66]. The ligand from
the copper complex has been found in the cytoplasm and it has been
suggested that it may recruit, in place of a copper chaperone, the
copper that is translocated and storedwithin themitochondrialmatrix
[66].
At least two homologues of Cox17p are present in the IMS, the
small soluble proteins Cox19p [67] and Cox23p [68], which also
contain twin Cx9C metal binding motifs and are required for COX
assembly. Cox23p does not physically interact with Cox17p in a stable
complex but the COX defect in cox23 mutants is suppressed by
exogenous copper in combination with COX17 overexpression. These
data have suggested that both proteins function in a commonpathway
with Cox17p acting downstream of Cox23p [68]. Cox19p is a copper-
binding protein [69] and could be part of the same copper distribution
pathway.
Cox17p transfers copper ions to two additional chaperones [70] that
facilitate copper insertion into the COX CuA and CuB active sites, Sco1p
[71] and Cox11p [72,73], respectively. These proteins are anchored to
the mitochondrial inner membrane (MIM) through a transmembrane
α-helix and expose their copper-binding sides in the IMSwhere copper
transfer occurs [62,74]. In vitro experiments have shown that soluble
truncated forms of both Cox11p and Sco1p are able to bind copper
donated from Cox17p [75,76]. It is still not clear, however, how the
transfer of copper occurs between Cox17p and these proteins because
physical interactions among them have not been detected [70].
High copy suppressor screens were essential to place Sco1p into
the COX copper delivery pathway. SCO1 was originally identiﬁed as
essential for COX assembly in yeast [77] and subsequently as a
multicopy suppressor of a cox17 null mutant [61]. Sco1p transfers
copper from Cox17p to Cox2p and has been shown to directly interact
with Cox2p [78]. Sco1p has a metal binding thioredoxin-like CX3C
motif analogous to the copper-binding motif of Cox2p and this motif is
essential for its function as demonstrated by site-direct mutagenesis
[79]. Themechanism of copper transfer from Cox17p and to Cox2p has
been recently reviewed [80]. Although the experimental data could
support a role for Sco1p in copper insertion, considering its structural
similarity to the protein family of disulﬁde reductases, it has been
proposed that it could rather be involved in the reduction of cysteines
in the Cox2p copper-binding site [81,82]. This reduction is necessary
for the co-factor incorporation [83,84]. Sco1p has the ability to form
homodimeric complexes [78] which could facilitate the performance
of both functions by the collaborative action of each monomer.
Yeast SCO1 has a highly conserved homologue, SCO2 [85]. However,
deletion of sco2 does not affect COX assembly [71]. SCO2 overexpres-
sion does not suppress the COX assembly defect of a sco1 null mutant
strain but it is able to partially rescue a sco1 point mutant [71]. SCO2
overexpression also suppresses cox17 mutations, although less efﬁ-
ciently than SCO1, and only when the growth media is supplemented
with copper [71]. These data were interpreted to indicate that yeast
Sco1p and Sco2p have overlapping but not identical functions [71].
Remarkably, humans also have two homologues of yeast Sco1p,
SCO1 and SCO2 [86], both of which are essential for COX assembly.
Mutations in SCO1 [26] and SCO2 [27–29] result in severe mitochon-
drial disorders described below. Functional complementation studies
have shown that expression of either human SCO1 or SCO2 does
not complement a yeast strain carrying a null allele of sco1 [87].
Interestingly, the expression of a chimeric proteinwith the N terminus
of yeast and the C-terminus (that contains the CX3C copper-binding
domain) of human SCO1 (but not of SCO2) is able to complement the
yeast mutant [87]. The functional differences among the two yeast and
human isoforms is explained by the fact that the two genes probably
originated from a duplication that occurred separately in the two
organisms [27].
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have been shown to perform independent, cooperative functions in
the process of COX assembly [88]. This is suggested by the fact that
overexpression of each SCO protein in ﬁbroblasts from patients with
mutation in the other SCO protein results in a dominant negative
phenotype [88]. In a proposed model, human COX17 delivers copper
to SCO2 which in turn transfers it directly to the CuA site in COX
subunit II in a reaction facilitated by SCO1 [88]. SCO2 could form a
heterodimer with SCO1, which could be required to create the Cu(II)–
Cu(I) dinuclear CuA site [89]. Recently, SCO1 and SCO2 were shown to
have additional regulatory roles in the maintenance of cellular copper
homeostasis cooperating to regulate copper efﬂux under conditions of
excessive cellular copper [90].
A better understanding of the pathophysiology of human disorders
associated with mutations in genes required for copper insertion in
COX has suggested new avenues for treatment of these disorders.
Speciﬁcally, mutations in SCO2 produce childhood onset cardioence-
phalomyopathy [27,28,30]. The addition of CuCl2 [91] or copper-
histidine (Cu-His) [91] to cultured cells from patients with SCO2
mutations improved the biochemical defect. The mechanism of
suppression remains unclear. As pointed out by Jaksch et al. [91],
suppression could result from the very low residual levels of SCO2 in
the patient cells, direct addition of copper to the CuA site, or by
another copper-binding protein. Whatever the mechanism, copper
supplementation has suggested a possible therapy for this mitochon-
drial disease. Cu-His has been used in the treatment of Menke's
disease (a neurological disorder produced by the loss of the copper-
transporting ATPase ATP7A) with some success [92] and the same
treatment may be effective for childrenwith SCO2mutations. Actually,
subcutaneous injection of Cu-His, a physiological compound found in
blood, in a patient affected by severe hypertrophic cardiomyopathy
associated with SCO2 mutations did induce hypertrophic regression
and ventricular function improvement with a signiﬁcantly longer
survival in comparison with all previously reported patients [93].
The CuB site located in Cox1p is formed by one copper ion
coordinated by three histidine ligands and present in close proximity
to the heme a moiety. The metallochaperone for the formation of the
CuB site of Cox1p is the product of COX11 [72,73]. Cox11p was initially
described in yeast as necessary for COX assembly [94] but its role in
CuB formation was ﬁrst shown in the prokaryote Rhodobacter
sphaeroides [72]. The COX assembly defect in cox11 yeast mutants is
not suppressed by exogenous copper and genetic suppressors of the
null mutants have not been obtained. However, Cox11p was shown to
bind Cu(I) [95]. The soluble C-terminal domain of Cox11p forms a
dimer that coordinates one Cu(I) per monomer. The two Cu(I) ions in
the dimer exist in a binuclear cluster and appear to be ligated by three
conserved cysteine residues [95]. Themechanism of copper transfer to
CuB remains to be elucidated.
2.3. Suppression of heme A biogenesis and insertion defects
The study of suppressors of heme A biosynthesis defects in yeast
and human cell lines has provided information of biological and
medical relevance.
Heme A is a unique heme compound present exclusively in COX. It
differs from protoheme (heme B) because it has a farnesyl instead of a
vinyl group at carbon C2 and a formyl instead of a methyl group at
carbon C8 [96]. The ﬁrst step of the heme A biosynthetic pathway is
the conversion of heme B to heme O, a reaction that is catalyzed by the
farnesyl-transferase Cox10p [97]. The subsequent oxidation of heme O
to heme A occurs in two discrete monooxygenase steps. The ﬁrst
consists of a monooxygenase-catalyzed hydroxylation of the methyl
group at carbon position 8 resulting in an alcohol that would be
further oxidized to the aldehyde by a dehydrogenase. The ﬁrst step is
catalyzed by Cox15p. In S. cerevisiae, Cox15p acts in concert with
ferredoxin (Yah1p) and the putative ferredoxin reductase Arh1p. Thetwo latter enzymes are probably necessary for the supply of electrons
to the oxygenase Cox15p [98–100]. Interestingly, in the yeast Schizo-
saccharomyces pombe COX15 and YAH1 are fused in a single gene [98].
At present, the identity of the putative gene product involved in the
oxidation of the alcohol resulting from the Cox15p action to the
corresponding aldehyde to yield heme A remains unknown.
The biosynthesis of heme A is regulated by downstream events in
the COX assembly process. By measuring the amount of heme A and
heme O in different yeast COX mutants it was observed that all the
mutants analyzed showed a drastic reduction of steady-state levels of
heme A, with the exception of shy1, cox20 and cox5a null mutants, in
which heme Awas still detectable at 10–25%. This amount is probably
associated with residual assembled COX [101]. The overexpression of
COX15 acted as a suppressor of the heme A accumulation defect in
COX mutants including mutants in which Cox1p was not synthesized.
This observation suggested that the absence of heme A in the mutants
is not due to a rapid turnover of the co-factor in the absence of COX
subunit 1, but rather to a feedback regulation of the heme A synthesis
when the COX assembly process is blocked. The COXmutants analyzed,
with the obvious exception of cox10, also showed an accumulation of
heme O, indicating that this compound is stable. In addition, the cox15
null mutant presented a very low amount of heme O, a phenotype that
was not rescued by the overexpression of COX10. This observation
suggested that the ﬁrst step of the heme A biosynthesis is also posi-
tively regulated in a Cox15p dependent manner [101]. This regulatory
system could be different in mammalian cells. Analyses of mitochon-
drial heme content in COX15 deﬁcient ﬁbroblasts from a human
patient suffering from hypertrophic cardiomyopathy showed levels of
heme O signiﬁcantly higher than in control ﬁbroblasts [33].
Pharmacological suppressor studies of the respiratory defect of
human ﬁbroblasts from patients with defects in components of the
mitochondrial respiratory chain, including mutants of COX10 [31], have
allowed the identiﬁcation of agents for possible use in therapeutic
approaches to combat these mitochondrial diseases. Speciﬁcally, it was
recently reported that treatment with bezaﬁbrate signiﬁcantly rescues
the respiratory defects in the mutant cells. Bezaﬁbrate is a widely used
hypolipidemic drug that acts as a highly speciﬁc Peroxisome Prolif-
erator-Activated Receptor (PPAR) agonist [102]. PPARs are ligand-
activated nuclear receptors involved in the regulation of several
energy metabolism genes, such as the ones encoding mitochondrial
fatty acid β-oxidation enzymes (reviewed in [103]). Supplementation
with 400 μM bezaﬁbrate for 72 h signiﬁcantly increases COX activity in
COX10 mutant ﬁbroblasts. This partial restoration of COX activity is
accompanied by complete restoration of cell respiration to normal levels
[104]. In the bezaﬁbrate-treated COX10 deﬁcient cells, the levels of both
mRNA and protein of the COXmitochondrial encoded subunit COX2 and
the COX nuclear-encoded subunit COX4 are increased to normal levels.
More importantly, the expression of the COX10mutated gene, encoding
for a partially functional protein, is also increased suggesting that the
increase in COX activity is due to improved COX assembly. Bastin et al.
dissected the bezaﬁbrate-mediated suppression mechanism. It was
previously reported that ﬁbrates are able to induce PPARδ-mediated
expression of PGC-1α (PPAR coactivator-1α) in mice muscle [105]. This
is in agreement with the existence of a PPAR response element in the
PGC-1α promoter [106]. PGC-1α up-regulates a large group of nuclear
genes encoding respiratory chain components or proteins involved in
mitochondria biogenesis, such as the mitochondrial transcription factor
A (Tfam). PGC-1α does not bind to the DNA, but rather activates the
nuclear respiratory factors 1 and 2 (NRF1 and NRF2) already bound to
the promoter of the target genes, namely genes involved in oxidative
phosphorylation (review in [107]). It is also known that PGC-1α induces
theexpressionofNRF1andNRF2 [108]. In thebezaﬁbrate-treatedCOX10
deﬁcient cells, PGC-1α expression increases about 2.5 fold compared to
untreated cells while an additional slight increase in themRNA levels of
NRF1 and Tfam is also observed [104]. Bezaﬁbrate treatment activates
PPARs which in turn directly induces PCG-1α expression and thereby
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activators leading to increased COX structural and assembly gene
expression. It seems clear that bezaﬁbrate suppression of COX10 defects
does not bypass COX10 function, but it is mediated by the increased
amounts of the partially functional COX10 concomitant with a general
increase in the expression of COX structural subunits. These results
support the possibility that therapeutic approaches aiming to increase
mitochondrial biogenesis can rescue to some extent partial oxidative
phosphorylation defects, including COX assembly deﬁciencies.
2.4. Suppression of defects affecting the formation of assembly
intermediates
Suppression studies of defects affecting the formation of assembly
intermediates have provided novel information concerning COX
assembly regulation and interactions among several COX assembly
factors.
COX assembly is characterized by a concerted accumulation of its
constitutive subunits. Data mainly obtained from studies performed
with yeast mutants indicate that most unassembled subunits,
particularly the ones forming the catalytic core, are post-translation-
ally degraded [110,111]. Recently, another contribution to the
stoichiometric accumulation of subunits during COX biogenesis in
the yeast S. cerevisiae has been reported. It consists of a regulatory
mechanism by which the synthesis of subunit 1 is down-regulated in
the absence of its assembly partners [112–115]. Decreased Cox1p
synthesis relative to other mitochondrial translation products was
previously reported as a secondary observation in several yeast COX
assembly mutants [116,117]. This phenotype could not be accounted
for by a defect in the translation system because the mutations were
not in proteins related to this mitochondrial activity [116,117]. A major
step in the characterization of this regulatory mechanism came from
studies aiming to understand the function of the COX assembly factor
Shy1p [118]. Shy1p function is of signiﬁcant interest because the
human homologue of SURF1 is responsible for cases of Leigh's
syndrome (LS) associated with COX deﬁciency, a severe neurological
disorder of childhood [24,25].
The study of respiratory deﬁcient strains carrying a null allele of
shy1 that spontaneously reverted to a respiratory-competent pheno-
type allowed the identiﬁcation ofMSS51 as a extragenic suppressor of
shy1 mutations. Both mutant forms of mss51 and overexpression of
the wild-type gene act as suppressors of shy1 null mutants by
increasing the levels of newly synthesized Cox1p [112]. Mss51p is
required for COX1 mRNA translation [114,119] and also plays a post-
translational role [113,114] as discussed below. Screens of a collection
of strains carrying null mutations of COX biogenesis factors showed
that the amount of newly synthesized Cox1p is not only reduced in
shy1 mutants, but also in most COX assembly mutants. In all these
mutants, the Cox1p synthesis defect is restored by the mss51 sup-
pressors of shy1 or by mutations in cox14, which codes for another
COX assembly factor [120]. Mss51p and Cox1p were shown to form a
transient complex [113,114] that is stabilized by Cox14p [38]. These
interactions have been postulated to down-regulate Cox1p synthesis
when COX assembly is impaired [38]. According to this model, the
release of Mss51p from the ternary complex and its availability for
additional Cox1p synthesis occur at a downstream step in the
assembly pathway, and is likely catalyzed by Shy1p [113,121]. The
unique properties of this regulatory mechanism offer a means to
catalyze multiple-subunit assembly [113,114,121]. In addition, reduced
Cox1p synthesis in the absence of COX assembly and resulting
degradation of the other core subunits will also limit the accumulation
of partially matured core subunits that, as recently proposed for yeast
subunit 1, could contribute to the production of unstable pro-oxidant
intermediates [122].
Coa1p was recently described as a new player in the subunit 1
synthesis regulatory loop [121,123]. Coa1p is a protein associated withthe inner mitochondrial membrane where it is part of the high molec-
ular weight complex containing Cox14p, Mss51p and newly synthe-
sized Cox1p [121,123]. The interaction Cox14p-Mss51p is unaffected in
a Δcoa1 mutant. In the absence of Cox14p, however, the binding of
Coa1p-Mss51p is disrupted suggesting that the interaction of Coa1p
with the Cox1p-Cox14p-Mss51p complex is mediated through Cox14p
(27). Shy1p is not part of the Cox1p-Cox14p-Mss51p-Coa1p complex
(27), but it has been shown to co-precipitate with Coa1p [121,123],
suggesting that these two factors probably interact once Mss51p has
disengaged from the complex (27). As for cox14mutants, mutations in
coa1 do not affect the synthesis but the accumulation of Cox1p in the
holoenzyme suggesting that Coa1p also plays a role in the feedback
regulation of Cox1p expression [121,123]. The COX assembly defect
in a coa1 null mutant strain can be suppressed by overexpression of
Mss51p and Cox10p [97]. Both suppressors can act synergistically
when the two proteins are co-expressed and thus link Coa1p to both
translational regulation and maturation of Cox1p [123]. Pierrel et al.
have speculated that Coa1p could stabilize the Cox1p-Cox14p-Mss51p
complex until Shy1p interacts with Coa1p in a step involving heme A
insertion into Cox1p and further progression in the assembly process
[123]. While Cox1p maturation certainly occurs within these initial
Cox1p complexes, the precise role of each factor remains to be
elucidated.
At present, it is not clear if Cox1p translation in other organisms is
also subject to regulation by downstream events. Mammalian homo-
logues of Mss51p, Cox14p and Coa1p have not been identiﬁed to date.
The precise function of SURF1/Shy1p in COX assembly is currently
unknown. However, data gathered by studying spontaneous suppres-
sor mutations and high copy suppressors of yeast shy1 mutants have
indicated that SURF1/Shy1p plays a role in the formation of an early
COX assembly intermediate containing subunit 1 as mentioned above.
Analysis of COX by Blue Native gel electrophoresis has indicated that
assembly of COX in SURF1 deﬁcient ﬁbroblasts is blocked at an early
step, most likely before the incorporation of subunit II into the nascent
intermediates composed of subunit 1 alone or subunit 1 plus subunit 4
and 5a [124–126]. In the COX assembly model originally proposed by
Nitjmans et al. [16], the ﬁrst subassembly (S1) is formed exclusively by
subunit 1, which acts as a seed for sequential incorporation of COX
subunits. In this model, the addition of subunits COX4 and COX5a
(yeast Cox5ap and Cox6p, respectively) to S1 results in the progression
to the second assembly intermediate (S2). Insertion of heme A into
COX1 probably occurs before the addition of subunits 4 and 5a, as
suggested by the accumulation of the COX1–COX4–COX5a intermedi-
ate in SCO1 and SCO2mutant ﬁbroblasts [36,126] but not in COX10 and
COX15 mutant cells [32,33,126]. These ﬁndings suggest that the pres-
ence of hemeA in COX1might stabilize its binding to COX4 and COX5a.
After the formation of the COX1–COX4–COX5a subassembly, the COX
assembly process continues with the formation of the third proposed
intermediate (S3) by the addition of the remaining structural subunits
with the exception of COX6a and COX7a/b (yeast subunits 10 and 7).
These subunits are added later to complete the holoenzyme [16,126].
This model has been reﬁned by recent observations. New analysis of
subassemblies in ﬁbroblasts from patients with SCO2 and SURF1
suggested that mammalian COX4 and COX5a subunits form a dimer
before their incorporation into S1 [36]. Noticeably, the equivalent yeast
Cox5p–Cox6p dimer was also detected in a yeast COXmutant inwhich
assembly is compromised in the latter stages of the process [40]. This
result is consistent with the observation that in yeast the presence
of subunit 6 is required for subunit 5 stability [127]. An additional
intermediate seems to exist between S2 and S3 and consists of at least
mammalian subunits COX1–COX2–COX4–COX5a [36]. COX2 may
associate with the COX1–COX4–COX5a intermediate upon its copper
metallation by the speciﬁc SCO1–SCO2 copper chaperones as sug-
gested by the observation that SCO1 and SCO2mutant ﬁbroblasts from
patients with COX deﬁciency accumulate the COX1–COX4–COX5a
intermediate [36,126].
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have provided insight into SURF1/Shy1p role within the COX assembly
process. However, it remains unclear whether the primary Shy1p
function is required for either Cox1p maturation, assembly or both.
Mss51p mediated suppression of yeast shy1 mutants [112] has been
shown to be enhanced by both co-overexpression of COX10 [123] and
co-overexpression of the COX subunits Cox5p and Cox6p [128]. The
presence of SURF1 orthologues in terminal oxidase operons of several
prokaryotes [129] in which COX contains the evolutionary conserved
core subunits (Cox1p, Cox2p, Cox3p) but not the other structural
subunits such as Cox5p and Cox6p suggests a role for SURF1/Shy1p in
forming the catalytic core of the enzyme. Studies in R. sphaeroides
have suggested that bacterial SURF1 is required for either insertion of
heme A at the a3 center or stabilization of the a3-CuB binuclear center
in COX1 [130]. The respiratory defect of yeast shy1 mutants is not
rescued by supplementation of the growth media with hemin [128].
Analyses of human COX assembly intermediates have shown that the
SURF1 deﬁcient ﬁbroblasts accumulate the S2 assembly intermediate.
They are similar in this respect to SCO1 and SCO2 deﬁcient ﬁbroblast
but differ from COX10 and COX15 deﬁcient ﬁbroblasts in which S2 is
not formed and only S1 accumulates as mentioned above [36,125,126].
These observations apparently argue against a primary role of Surf1p
in heme A insertion. Exogenous copper, however, partially suppresses
the respiratory defect of a yeast shy1 null mutant strain by a
mechanism that remains to be characterized [128]. Although Shy1p
could play a direct or indirect role in Cox1p maturation, the possibility
of a SURF1/Shy1p role in facilitating the addition of subunit 2 to the
Cox1p–5p–6p complex cannot be excluded. Further support for the
role of Shy1p as an assembly factor was recently reported by showing
that Shy1p promotes COX biogenesis through association with
different protein modules, which are potential COX assembly inter-
mediates containing Cox1p and Cox5p, among other proteins [121]. In
addition, Shy1p and Cox14p were also found to interact with partially
and fully assembled forms of COX associated with complex III of the
mitochondrial respiratory chain [121], which suggests that these two
COX assembly factors play chaperone roles beyond the early stages of
COX assembly.
Finally, our group has recently reported that overexpression ofHAP4
suppresses the respiratory deﬁcient phenotype of yeast shy1 null and
point mutant strains [128]. Hap4p is the catalytic subunit of the CCAAT
binding site transcriptional activator Hap2p,3p,4p,5p (HAP) complex
which globally activates transcription of nuclear genes involved in
mitochondrial respiration during the transition from fermentation to
respiration [131]. HAP4 overexpression in strains carrying null alleles ofFig. 2. Mechanisms of suppression of the COX assembly defect of yeast shy1 mutants. After
groups, before or during the formation of an assembly intermediate containing Cox5ap and
could play a role in either Cox1p maturation or assembly. Mutant and additional copies ofms
overexpression of Hap4p suppresses largely by increasing the amount of Cox5ap–Cox6p. Thcox10, cox11, cox14, cox15, cox16, cox17, oxa1,mss51 and pet191 failed to
induce any suppression of their respiratory growth defect. This obser-
vation indicated that the suppression by HAP4 was speciﬁc to the shy1
null mutant and suggested a speciﬁcmechanism ofHAP4 suppression in
this strain.
It was previously reported that overexpression of the HAP4 gene
was able to suppress the respiratory defect of a strain carrying a
deletion of thematrix domain ofOxa1p although it did not compensate
for the total absence of Oxa1p [132], in agreement with our results.
Oxa1p is a key component of the machinery for the insertion of
membrane proteins in mitochondria [133]. The protein interacts with
nascent mitochondrial polypeptides [133] and it has been proposed to
mediate the co-translational insertion of mitochondrially encoded
subunits through an interaction of its C-terminal tail located in the
mitochondrial matrix with the mitochondrial ribosome [134,135].
Additionally, Oxa1p seems essential for the translocation of the
hydrophilic domain of Cox2p [136–138]. The mechanism of the oxa1
suppression byHAP4 remains to be elucidated. Hlavacek et al. reported
an increase in the expression of Cox2p and proposed that this fact
alone or in combination with an increase in the expression of other
respiratory subunits byHAP4overexpression could compensate for the
defect in co-translationalmembrane insertion of these subunits due to
the oxa1mutation [132].
In the case of the shy1 null mutants, the speciﬁcity of HAP4
suggested that it could act by either increasing the expression of a
protein with an overlapping function with Shy1p or the amount of
speciﬁc COX subunits and/or assembly factors favoring amore efﬁcient
assembly of COX. In this case, the shy1 suppression by HAP4 was
demonstrated to bemediated bya speciﬁc increase in the expression of
subunits Cox5p and Cox6p, the partners of Cox1p in early COX
subassemblies [128]. These results give support to the notion that
Shy1p could act by promoting/stabilizing the formation of assembly
intermediates. Some of the described suppressor mechanisms of shy1
mutants are summarized in Fig. 2.
The HAP complex is conserved from yeast to mammals where the
human complex, termed NF-Y, contains three subunits, NF-YA, B and C.
The proteins share homology to Hap2p, 3p and 5p, respectively. Some
of the subunits are interchangeable across species. For example,
human NF-YA, which contains both a DNA binding domain and a
Q-rich activation domain, complements the respiratory defect of a
hap2 yeast mutant [139]. Interestingly, overexpression of NF-YA, the
catalytic subunit of the human NF-Y complex, is able to increase
mitochondrial COX activity in SURF1 deﬁcient ﬁbroblasts through a
mechanism that remains to be characterized [128].Cox1p synthesis, this subunit is matured by insertion of heme A and copper prosthetic
Cox6p. This ternary complex will subsequently assemble with metallated Cox2p. Shy1p
s51 act as shy1 suppressors by increasing the amount of newly synthesized Cox1p, while
is ﬁgure has been reproduced with permission from [128].
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complex is not the main activator of transcription of nuclear genes
involved in mitochondrial biogenesis and oxidative phosphorylation
in mammals. The mammalian respiratory genes are known to be
regulated by a variety of transcription factors, most notably NRF-1
and NRF-2 [140]. However, expression of at least two key proteins of
the mammalian mitochondrial translational machinery, mitoriboso-
mal protein S12 (Mrps12) and mitochondrial seryl-tRNA ligase, was
recently shown to be regulated by NF-Y [141]. Since NF-Y regulates
expression of genes in the fatty acid synthesis and oxidation
pathways, its stimulatory effect on mitochondrial biogenesis could
be indirect as reported for other transcriptional factors such as the
PPARδ in skeletal muscle [142]. Other examples include the
transcriptional co-activators PGC-1α and PGC-1β overexpression in
osteosarcoma cybrid cells carrying MTCOX1 mutations (amount of
PGC-1α transcripts were 44-fold higher than in the controls)
stimulated mitochondrial biogenesis and respiration [143]. As
mentioned in the previous section for the treatments with PPAR
agonists, these results suggest therapeutic approaches to combat COX
and other oxidative phosphorylation partial defects. These
approaches aim to increase mitochondrial biogenesis thus compen-
sating for the partial respiratory defect. However, it is important
to note that in some cases, pharmacological agents can fail to mimic
the effects of speciﬁc transcriptional activators overexpression pro-
bably because their milder effect. For example, bezaﬁbrate treatment,
which increases PGC-1α expression by 2.5 fold as mentioned earlier,
is unable to suppress the COX lesion of mutant human SURF1 de-
ﬁcient ﬁbroblasts [104]. These cells carry a homozygous mutation in
SURF1 that produces a truncated unstable protein [109]. Bezaﬁbrate
treatment to SURF1 deﬁcient cells leads to increased SURF1 mRNA,
but the translated SURF1 protein does not accumulate [104]. It is
possible to speculate that bezaﬁbrate failed to suppress the COX
defect in these cells because the enhanced expression of COX struc-
tural subunits induced by the 2.5-fold increased amounts of PGC-1α
did not reach the threshold of accumulated proteins required to
effectively bypass the absence of SURF1.
3. Concluding remarks
The isolation and characterization of genetic and metabolic
suppressors of COX assembly defects in yeast strains and cell lines
derived from human patients have provided signiﬁcant amount of
information concerning the assembly of this enzyme. Suppressor
studies have made possible the identiﬁcation of many COX assembly
ancillary factors, the characterization of their functions and the
understanding of the pathways in which they operate. The informa-
tion gathered from these studies is also proving to be useful for
devising therapeutic approaches for the management of human
disorders associated with COX deﬁciency.
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